Merck’s new drug development moving forward, sales increase
Merck reported Q3 sales of $18.085B, up 4% YoY, and GAAP EPS of $2.04. The company highlighted advancements in its drug pipeline, including a potential therapeutic cancer vaccine in Phase 3 testing. Merck's stock rose 4.7% to $147.53 at market open. Keytruda sales increased 6% to $8.601B, driven by global demand in various cancer indications.
How this was made
The 30-second read
Why it matters
The article combines a Q3 financial beat with multiple regulatory catalysts (FDA approvals, accepted BLAs/sNDAs, and PDUFA dates) and incremental sales growth drivers, which can shift near-term expectations for pipeline probability and revenue durability.
Market read
Traders can reassess Merck’s pipeline regulatory timeline and near-term earnings power given the Q3 beat and the newly disclosed approvals/accepted filings with dated FDA review milestones.
What to watch
The piece notes sales offsets (BRIDION, JANUVIA/JANUMET, LAGEVRIO declines) and a one-time EPS charge tied to a license agreement, which could temper how much the market extrapolates from the beat.
Background
Merck is navigating the approach to Keytruda patent expiry in 2028 while trying to de-risk late-stage pipeline assets across oncology and infectious diseases.
Ticker impact
Merck reports Q3 results plus multiple fresh regulatory milestones, including FDA approvals and accepted BLAs/sNDAs with specific PDUFA dates.
Likely upward bias as investors price in reduced regulatory uncertainty and continued growth from KEYTRUDA, WINREVAIR, and ENFLONSIA.
The article ties Merck’s stock strength to Q3 beat and highlights several FDA/EC/Japan approvals and accepted applications with named PDUFA timelines, which are actionable catalysts for biotech/pharma risk pricing.
Market effects
Reinforces positive read-through for oncology and immunotherapy peers as Merck’s ADC, vaccine, and checkpoint-adjacent pipeline advances through late-stage milestones.
Limited direct regional spillover beyond US regulatory timelines, though Europe/Japan approvals support broader global demand expectations.
Highlights ongoing global regulatory momentum for oncology combinations and RSV/HIV prevention and treatment programs.
Counterpoint
Despite pipeline progress, the article emphasizes Keytruda patent loss in 2028, so near-term approvals may not fully offset longer-term revenue risk.
Key entities
- companyMerck
US-listed pharmaceutical company reporting Q3 results and multiple regulatory milestones across oncology and infectious diseases.
- drugKeytruda
Merck’s blockbuster cancer therapy referenced as facing patent loss in 2028, while still showing strong quarterly sales growth.
- drugENFLONSIA
RSV prevention product whose supplemental BLA acceptance expands pediatric indication; PDUFA date set for March 22, 2027.
- combinationWELIREG plus Lenvima
FDA-approved combination for advanced renal cell carcinoma in certain previously treated adult patients.
- drugWINREVAIR
Pulmonary arterial hypertension therapy with a US label update based on HYPERION trial data.




